Company intelligence / Profile preview

T3S Technologies

Salt Lake City, Utah, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

T3S Technologies provides a proprietary bacterial type III secretion-based platform and associated strain/codon optimization services to express and secrete difficult-to-express recombinant proteins for partners from development through manufacturing; it does not appear to run its own therapeutic clinical trials and instead operates as a technology and services provider.[1][2][3][7][10]

Modalities: ProteinRecombinant protein
Industry: Non-Drug Biotech

Partnerships

Vectron Biosolutions (acquisition of T3S secretion platform; ongoing use of platform in Vectron’s offering)[3]

Beyond the preview

Go deeper on T3S Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3S Technologies.

Explore the full profile